Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
EXCLUSIVE: In a surprising move, Representative Ro Khanna from California’s Democratic party has pivoted from his usual opposition to President Donald Trump’s policies. Instead, he has adopted a diplomatic approach toward the president’s latest executive order concerning prescription drug prices. Khanna, known for his vocal criticism of Trump’s tariff and deportation policies, is now focused on bipartisan legislation.
On Wednesday, Khanna unveiled a proposal aimed at codifying Trump’s executive order designed to lower drug prices for Americans. This shift highlights Khanna’s desire to reach across party lines to deliver significant benefits for everyday citizens. He is actively encouraging his Republican colleagues to join him in this effort, showcasing a willingness to collaborate for the greater good.
Khanna explained his rationale by stating, “President Trump’s executive order specifies that Americans should not pay more for medications than citizens in other countries. It empowers Cabinet secretaries to challenge pharmaceutical companies that engage in price gouging. Although Trump encountered legal resistance in his previous administration, we must take decisive action. My proposal aims to cement the language from Trump’s initiative into law, and I am hopeful for Republican sponsorship,” he shared in an exclusive interview.
As Democratic leaders grapple with party unity following setbacks in recent elections, there has been a pronounced rejection of any association with Trump. Protests and tensions have proliferated among party ranks as they struggle to find a cohesive identity. Yet Khanna stands apart, indicating that he values the welfare of the American public over strict party loyalty. “If Donald Trump proposes a beneficial policy, I won’t oppose it solely for political gain,” he asserted.
Khanna’s perspective is unique; he recognizes the need for pragmatic action regardless of political affiliations. “If Trump’s ideas serve to improve the lives of Americans, I am willing to back them. However, if they conflict with my values, I will voice my concerns. My ultimate test is whether the proposed solution genuinely helps people,” he elaborated.
Although he has yet to communicate with Trump directly regarding the codification of the executive order, Khanna delivered a compelling speech on the House floor, calling for bipartisan support in the fight against high prescription drug costs.
“Are you aligned with the American people, or do you side with the $16 billion spent by Big Pharma lobbyists last year? My legislation is straightforward. It encompasses President Trump’s idea, his language, made into law. I urge every Republican and Democrat to perceive this as a bipartisan opportunity to aid the public,” he challenged.
In the lead-up to Trump’s order signing, Khanna reaffirmed his commitment to lowering drug prices. He pointed out his previous collaboration with Senator Bernie Sanders, emphasizing the necessity of legislative changes aligned with the goal of fair drug pricing. “It stands to reason that every American understands the burden of soaring prescription costs. It is fundamentally unfair that U.S. citizens face exorbitant bills while patients in other countries pay a fraction of the cost. It’s time we rectify this situation,” he asserted.
As Khanna, who served as a surrogate for Joe Biden’s 2024 campaign, seeks common ground with the current administration, he voiced strong opinions on Biden’s candidacy. During an appearance on “The Story,” Khanna stated bluntly, “Given the current landscape, it seems clear that Biden should not have run this time around.”
He continued, emphasizing the importance of accountability within the party, “We need to openly acknowledge that there should have been an open primary. At this point, it is essential for Democrats to confront the reality of our situation and be straightforward with the American electorate about our missteps.”
During his initial defense of Biden, Khanna admitted he lacked a complete understanding of the president’s health and cognitive abilities. He further stated, “Now, it’s time for us as a party to own the mistakes we made in the past and recognize our responsibility to the public.”
This recent effort by Khanna serves as a beacon of potential collaboration between the two major parties, particularly in an era where policymaking appears increasingly fragmented. His willingness to embrace Trump’s vision for lowering drug prices could signal a new chapter in bipartisan cooperation, especially if it results in tangible benefits for the American populace.
As negotiations unfold regarding drug pricing legislation, the implications of Khanna’s move will likely be keenly observed by both Democrats and Republicans. With public sentiment increasingly focused on healthcare affordability, Khanna’s initiative may prove to be a pivotal point for fostering collaboration and achieving meaningful reforms.
